SYDNEXIS, INC.
Sydnexis focuses on advancing innovation to treat pediatric progressive myopia, which is the leading cause of vision loss in children, by addressing a critical gap in care.
Funding history
About SYDNEXIS, INC.
How much funding has SYDNEXIS, INC. raised?
SYDNEXIS, INC. has raised $21.0M in total funding. The most recent round was Series B.
Where is SYDNEXIS, INC. headquartered?
SYDNEXIS, INC. is headquartered in Del Mar, CA.
What does SYDNEXIS, INC. do?
Sydnexis focuses on advancing innovation to treat pediatric progressive myopia, which is the leading cause of vision loss in children, by addressing a critical gap in care.
What problem does SYDNEXIS, INC. solve?
Pediatric progressive myopia is the leading cause of vision loss in children, but current treatments like glasses only manage symptoms, and specialty contact lenses that slow progression aren't suitable for younger children.
What's SYDNEXIS, INC.'s solution?
Sydnexis is advancing a pharmaceutical approach intended to slow myopia progression at an early age, aiming to help preserve vision in growing eyes.
What makes SYDNEXIS, INC. different?
The company points to results from its SYD-101 'Star Study' and positions its pharmaceutical approach as addressing younger children specifically, a group current specialty lens options don't serve.
What makes SYDNEXIS, INC. notable?
Raised a $45M Series B from RA Capital, Longitude Capital, Visionary Ventures and Bluestem Capital to develop a drug for pediatric myopia progression.
Leadership
Related terms
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated September 3, 2026.
🏷 Embed this badge
Building or fundraising? Add this to your site to show you're listed on SoCal.Startups — the link back helps other founders and investors find you here too.
